TrialThe Journal of urology2022

Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.

Max Kates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.